Company / Cash & Equivalents
TREACE MEDICAL CONCEPTS, INC. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$10.7M
FY2025
5-year range
$10.7M / $105.8M
FY2021-FY2025
Trend
-5.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $106M in FY2021 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 3-year CAGR of -18.1%.
Declined from $13M to $11M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -18.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TREACE MEDICAL CONCEPTS, INC.'s cash & equivalents has declined for 4 consecutive years.
- 3-year CAGR of -18.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 5.7% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.7M | -5.7% |
| FY2024 | $11.3M | -12.6% |
| FY2023 | $13.0M | -33.3% |
| FY2022 | $19.5M | -81.6% |
| FY2021 | $105.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026